Doximity, Inc. Class A Common Stock (DOCS)

Doximity currently trades at $57.04 per share and has shown little upside over the past six months, posting a small loss of 1.4%.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how vertical software stocks fared in Q1, starting with Olo (NYSE:OLO).

DOXIMITY INC (NYSE:DOCS) meets key quality investing criteria with strong revenue growth, high ROIC, and zero debt. Its profitability and cash flow conversion make it a standout in the healthcare technology sector.

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the vertical software industry, including Upstart (NASDAQ:UPST) and its peers.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Doximity (NYSE:DOCS) and the best and worst performers in the vertical software industry.

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the vertical software stocks, including Q2 Holdings (NYSE:QTWO) and its peers.

DOXIMITY INC (NYSE:DOCS) shows strong growth, high profitability, and a technical setup suggesting a potential breakout, making it a stock worth watching.

Healthcare professional network Doximity (NYSE:DOCS) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 17.1% year on year to $138.3 million. Its non-GAAP EPS of $0.38 per share was 39.3% above analysts’ consensus estimates.

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.

Rivian Automotive is better than this EV rival that missed analyst estimates of $250 million, according to Benzinga Pro.

A significant trading signal occurred for Doximity stock at a price of $49.24, after which DOCS rose up to 7.8%.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Wall Street ended the week higher, driven by trade optimism despite weak consumer confidence data and mixed corporate earnings.

Shares of healthcare professional network Doximity (NYSE:DOCS) fell 11.7% in the afternoon session after the company reported weak first quarter 2025 results: its revenue guidance for next year fell short of Wall Street's estimates and suggested a significant slowdown in demand. Notably, top-line growth decelerated significantly, up 17% (versus 25% growth in the previous quarter).